Compared with placebo, allocation to an SGLT2 inhibitor reduced the risk of acute kidney injury by 23% overall (RR 0·77, 95% CI 0·70–0·84), with similar reductions observed in patients with diabetes (0·79, 0·72–0·88) and patients without diabetes (0·66, 0·54–0·81; heterogeneity p=0·12; figure 1). This evidence concerns the gene SLC5A2 and diabetes mellitus.